ClinicalTrials.gg
RecruitingNCT04886804Updated Nov 12, 2026

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

A Phase 1 interventional study of zongertinib in Neoplasm Metastasis and Non-Small Cell Lung Cancer, sponsored by Boehringer Ingelheim. Recruiting at 85 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 4 months later.
Updated Nov 12, 2026Now RecruitingSite recruiting status changed+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
554
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,054 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 542 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
98th of 1,863
554 · median 43
Started
2021
with 133 others
Phase 1
709 of 2,054
128 open now
Primary completion
2028-02
later than 360 of 540 live
Registered
1,537th of 2,054
by date

Among the 2,054 studies in Neoplasm Metastasis with a site in United States, this one is the 98th largest by planned enrollment of the 1,863 interventional ones that give a count, is one of 134 that started in 2021, is one of 709 in phase 1, reaches primary completion later than 360 of the 540 other live ones, and was the 1,537th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,054 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,054 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful.

The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene.

The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to test whether zongertinib can make tumours shrink.

In this study, zongertinib is given to people for the first time. Participants take zongertinib as tablets once a day or twice a day.

The participants are in the study for as long as they benefit from and can tolerate treatment.

Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by zongertinib.

03

Conditions studied

  • Neoplasm Metastasis
  • Non-Small Cell Lung Cancer
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of an advanced, unresectable and/or non-haematologic . Patient must show presence of at least one according to (RECIST) 1.1.
  • (ECOG) score of 0, 1 or 2 (ECOG=2 only for Cohorts 6, 7 and 9) .
  • Availability and patient willingness to provide a sample of tumour for confirmation of the patient´s Human epidermal growth factor receptor 2 () status. This sample can be archival material obtained at any time prior to study enrollment.
  • Patient willing and able to comply with the protocol requirements for tumour (biopsies from are not allowed).
  • Adequate organ function defined as all of the following:

    • (ANC) ≥ 1.5 x 10\^9/L (≥ 1.5 x 10\^3/μL) (≥ 1500/mm\^3); ≥ 9.0 g/dL (≥ 90 g/L) (≥ 5.6 mmol/L); ≥ 100 x 10\^9/L (100 x 10\^3/μL) (100 x 10\^3/mm3) without the use of hematopoietic growth factors within 4 weeks of start of trial medication.
    • Total ≤ 1.5 times the (ULN), except for patients with Gilbert's syndrome: total bilirubin ≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN.
    • Estimated (eGFR) ≥ 50 mL/min - calculated using Chronic Kidney Disease Epidemiology (CKD-EPI) formula (≥ 30 mL/min/1.73m² for cohorts 6, 8, and 9).
    • (AST) and alanine transaminase (ALT) ≤ 3 x ULN if no demonstrable liver metastases, or otherwise ≤ 5 x ULN if transaminase elevation is attributable to liver metastases.
    • Alkaline Phosphatase \< 5 x ULN.
  • Recovered from any previous therapy-related toxicity to ≤ (CTCAE) Grade 1 at start of treatment (except for alopecia, stable sensory neuropathy and hypothyroidism (patients on thyroid replacement therapy) which must be ≤ CTCAE Grade 2)
  • of at least 12 weeks at the start of treatment in the opinion of the investigator.
  • At least 18 years of age at the time of consent or over the legal age of consent in countries where that is greater than 18 years.
  • Signed and dated written in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
  • Male or female patients. Women of (WOCBP) and men who are able to father a child must be ready and able to use highly effective methods of per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.

Additional inclusion criteria for Phase Ia

  • Patients with a documented diagnosis of HER2 aberration: overexpression OR gene amplification OR non-synonymous somatic mutation OR gene rearrangement involving HER2 or Neuregulin 1 (NRG1)
  • Patient who has failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options. Patient must have exhausted, or not be a suitable candidate for, available treatment options known to prolong survival for their disease

Additional inclusion criteria for Phase Ib - Cohort 1 only

  • Non-squamous non-small cell lung cancer (NSCLC) patients with documented human epidermal growth factor receptor 2 (HER2) mutation in the tyrosine kinase domain (TKD) as per local lab results.
  • Patient who had received, in the advanced/metastatic setting, at least one . Patients with non-squamous NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.

Additional inclusion criteria for Phase Ib - Cohort 2 only

  • Non-squamous NSCLC patient with a documented HER2 mutation in the tyrosine kinase domain (TKD) as per local lab results.
  • Treatment naïve for non-squamous NSCLC.

Additional inclusion criteria for Phase Ib - Cohort 3 only

  • NSCLC Patient with a documented HER2 mutation outside of the tyrosine kinase domain (TKD) as per local lab results or squamous NSCLC patient with mutation in the TKD as per local lab results. After implementation of CTP v8, only non-squamous NSCLC patients with a documented activating HER2 mutation outside of the tyrosine kinase domain (TKD) as per local lab results.
  • Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy. After implementation of CTP v8, patients who had received, in the advanced/metastatic setting, at least one line of systemic therapy OR patients who are treatment naïve for non-squamous NSCLC (no prior systemic therapy, immunotherapy or targeted therapy for stage IIIB or IV adenocarcinoma).

Additional inclusion criteria for Phase Ib - Cohort 4 only

  • NSCLC patients with documented HER2 mutation in the TKD as per local lab results.
  • NSCLC patients who are either treatment naïve or who had received any prior line of treatment, in the advanced/metastatic setting. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
  • Patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation.

Additional inclusion criteria for Phase Ib - Cohort 5 only

  • Non-squamous NSCLC patients with documented HER2 mutation in the TKD as per local lab results.
  • Patient should have received, in the advanced/metastatic setting, at least one line of systemic therapy that includes a platinum-based combination chemotherapy and should have been treated with previous HER2 directed antibody-drug conjugates (ADC) in the same advanced/metastatic setting and developed disease progression recurrence during or after completing this therapy. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.

Additional inclusion criteria for Phase Ib - Cohort 6 only

  • Non-squamous NSCLC patient with documented HER2 mutation in the TKD as per local lab results.
  • Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy.
  • Patient without active brain metastases or patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation.
  • Patient who is not eligible for any other recruiting cohort.

Additional inclusion criteria for Phase Ib - Cohort 7 only

  • Non-squamous NSCLC patient with documented HER2 mutation in the TKD as per local lab results.
  • Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy.
  • Patient without active brain metastases or patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation.
  • Patient who is not eligible for any other recruiting cohort.

Additional inclusion criteria for Phase Ib - Cohort 8 only

  • Treatment naïve for NSCLC
  • NSCLC (adenocarcinoma or squamous) patient with documented HER2 mutation in the tyrosine kinase domain (TKD) or non-squamous NSCLC with a documented HER2 mutation in the non tyrosine kinase domain (non TKD) as per local lab results

Additional inclusion criteria for Phase Ib - Cohort 9 only

  • Non-squamous NSCLC patient with documented HER2 mutation in the TKD as per local lab results.
  • Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.

Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to first trial treatment or planned within 6 months after screening
  • Previous or concomitant other than the one treated in this trial within the last 2 years, except:

    • effectively treated non-melanoma skin cancers
    • effectively treated carcinoma in situ of the cervix
    • effectively treated ductal carcinoma in situ
    • other effectively treated malignancy that is considered cured by local treatment.
  • Treatment with a systemic anti-cancer therapy or drug within 21 days or 5 half-lives (whichever is shorter) of the first treatment with the study medication
  • Patients who must or wish to continue the intake of restricted medication or any drug considered likely to interfere with the safe conduct of the trial
  • Previous treatment with zongertinib.
  • Radiotherapy within 2 weeks prior to first study treatment, except palliative radiotherapy to regions other than the chest, which is allowed up to 1 week prior to first study treatment.

Further exclusion criteria apply.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
554 participants (estimated)

Study arms

  • Experimental
    Phase Ia - Dose escalation part

    Consecutive cohorts of patients treated with escalating doses of BI 1810631 monotherapy.

    Drug: zongertinib

  • Experimental
    Phase Ib - Dose expansion part: Cohort 1

    Drug: zongertinib

  • Experimental
    Phase Ib - Dose expansion part: Cohort 2

    Drug: zongertinib

  • Experimental
    Phase Ib - Dose expansion part: Cohort 3

    Drug: zongertinib

  • Experimental
    Phase Ib - Dose expansion part: Cohort 4

    Drug: zongertinib

  • Experimental
    Phase Ib - Dose expansion part: Cohort 5

    Drug: zongertinib

  • Experimental
    Phase Ib - Dose expansion part: Cohort 6

    Cohort only in the United States of America (USA)

    Drug: zongertinib

  • Experimental
    Phase Ib - Dose expansion part: Cohort 7

    Cohort only in Japan

    Drug: zongertinib

  • Experimental
    Phase Ib - Dose expansion part: Cohort 8

    Cohort only in the United States of America (USA)

    Drug: zongertinib

  • Experimental
    Phase Ib - Dose expansion part: Cohort 9

    Cohort only in China

    Drug: zongertinib

Interventions

  • zongertinib

    Also known as: BI 1810631, Hernexeos®

06

What researchers measure

Primary outcomes

  1. Phase Ia: Maximum Tolerated Dose (MTD)

    Maximum tolerated dose is defined as the highest dose with less than 25% risk of the true Dose Limiting Toxicity (DLT) rate being equal to or above 33% during the MTD evaluation period in any studied regimen.

    Time frame: At the end of Cycle 1 (each cycle is 21 days).

  2. Phase Ia: Number of patients with Dose Limiting Toxicities (DLTs) in the MTD evaluation period

    Time frame: At the end of Cycle 1 (each cycle is 21 days).

  3. Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response (OR) as assessed by central independent review

    OR is defined as best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, from the first treatment administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anticancer therapy, loss to follow-up or withdrawal of consent.

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  4. Phase Ib - Cohorts 3 (patients prior to CTP v8.0), 6, 7, 8, and 9: Objective response according to RECIST 1.1 by investigator assessment

    Clincal Trial Protocol version 8.0 = CTP v8.0

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  5. Phase Ib: Cohort 4: Objective response according to Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) by central independent review

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

Secondary outcomes

  1. Phase Ia: Number of patients experiencing DLTs during the entire treatment period

    Time frame: From the start of the trial treatment until end of month 8, up to 8 months.

  2. Phase Ia: Maximum measured concentration of zongertinib in plasma (Cmax)

    Time frame: On day 1 and on day 15 of Cycle 1 (each cycle is 21 days).

  3. Phase Ia: Area under the concentration-time curve of zongertinib in plasma (AUC0-t2)

    Time frame: On day 1 and on day 15 of Cycle 1 (each cycle is 21 days).

  4. Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Duration of objective response (DoR) according to RECIST 1.1

    DoR is defined as the time from first documented complete response (CR) or partial response (PR) until the earliest of disease progression or death among patients with objective response as assessed by central independent review.

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  5. Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control (DC)

    DC is defined as best overall response of complete response (CR) or partial response (PR) or stable disease (SD) where best overall response is defined according to RECIST version 1.1 as assessed central independent review, from first treatment administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent.

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  6. Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Progression-free survival (PFS)

    PFS is defined as the time from first treatment administration until tumor progression according to RECIST version 1.1 as assessed by central independent review, or death from any cause, whichever occurs earlier.

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  7. Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response according to response assessment in RANO-BM criteria as assessed by central independent review for patients with central nervous system (CNS) lesions at baseline

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  8. Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control according to RANO-BM criteria as assessed by central independent review for patients with CNS lesions at baseline

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  9. Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response in CNS lesions according to RECIST 1.1 criteria as assessed by central independent review for patients with CNS lesions at baseline

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  10. Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control in CNS lesions according to RECIST 1.1 criteria as assessed by central independent review for patients with CNS lesions at baseline

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  11. Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Duration of objective response according to RECIST 1.1 by investigator assessment

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  12. Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Disease control according to RECIST 1.1 as assessed by the investigator

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  13. Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Progression-free survival according to RECIST 1.1 as assessed by the investigator

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  14. Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Objective response according to RANO-BM criteria as assessed by the investigator for patients with CNS lesions at baseline

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  15. Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Disease control according to RANO-BM criteria as assessed by the investigator for patients with CNS lesions at baseline

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  16. Phase Ib - Cohort 4: Duration of objective response (DoR) according to RANO-BM by central independent review

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  17. Phase Ib - Cohort 4: Disease control (DC) according to RANO-BM by central independent review

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  18. Phase Ib - Cohort 4: Progression-free survival (PFS) according to RANO-BM as assessed by central independent review

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  19. Phase Ib - Cohort 4: DoR in CNS lesions according to RECIST 1.1 by central independent review

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  20. Phase Ib - Cohort 4: DC in CNS lesions according to RECIST 1.1 by central independent review

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  21. Phase Ib - Cohort 4: PFS in CNS lesions according to RECIST 1.1 as assessed by central independent review

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  22. Phase Ib - Cohort 4: OR according to RECIST 1.1 by central independent review

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  23. Phase Ib - Cohort 4: Duration of OR according to RECIST 1.1 by central independent review

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  24. Phase Ib - Cohort 4: DC according to RECIST 1.1 by central independent review

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  25. Phase Ib - Cohort 4: PFS according to RECIST 1.1 by central independent review

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  26. Phase Ib - All cohorts: Overall survival (OS), defined as time from first treatment administration until death from any cause

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  27. Phase Ib - All Cohorts: Number of patients experiencing DLTs during the entire treatment period

    Time frame: From the start of the trial treatment until end of month 12, up to 12 months.

  28. Phase Ib - All Cohorts: Change from baseline to Day 1 of Cycle 5 in EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) physical functioning domain score

    Time frame: Baseline and on Day 1 of Cycle 5 (each cycle is 21 days).

  29. Phase Ib - All Cohorts: Change from baseline to Day 1 of Cycle 5 in Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) total score

    Time frame: Baseline and on Day 1 of Cycle 5 (each cycle is 21 days).

  30. Phase Ib - All Cohorts: Change from baseline to Day 1 of Cycle 5 in EORTC item List 46 (IL46) score

    Time frame: Baseline and on Day 1 of Cycle 5 (each cycle is 21 days).

07

Study locations

34 of 85 sites recruiting
08

References and documents

Publications

  • Heymach JV, Yamamoto N, Girard N, Ruiter G, Smit EF, Planchard D, Nadal E, Wu YL, Zugazagoitia J, Tu HY, Baik CS, Yoh K, Soo RA, Zhao Y, Sabari JK, Wermke M, Scheffler M, Ahn MJ, Fernamberg K, Schroeter L, Sadrolhefazi B, Thamer C, Eigenbrod-Giese S, Popat S; Beamion LUNG-1 Investigators. First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2026 Apr 30;394(17):1675-1684. doi: 10.1056/NEJMoa2516969. Epub 2026 Apr 15. PubMed 41985129 ↗
  • Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, Wu YL, Cho BC, Yamamoto N, Sabari JK, Zhao Y, Tu HY, Yoh K, Nadal E, Sadrolhefazi B, Rohrbacher M, von Wangenheim U, Eigenbrod-Giese S, Zugazagoitia J; Beamion LUNG-1 Investigators. Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025 Jun 19;392(23):2321-2333. doi: 10.1056/NEJMoa2503704. Epub 2025 Apr 28. PubMed 40293180 ↗
  • Heymach JV, Opdam F, Barve M, Tu HY, Wu YL, Berz D, Schroter L, Botilde Y, Sadrolhefazi B, Serra J, Yoh K, Yamamoto N. HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. J Clin Oncol. 2025 Apr 10;43(11):1337-1347. doi: 10.1200/JCO-24-01727. Epub 2025 Mar 3. PubMed 40030100 ↗
  • Heymach J, Opdam F, Barve M, Gibson N, Sadrolhefazi B, Serra J, Yamamoto N. A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations. Clin Lung Cancer. 2023 Mar;24(2):e65-e68. doi: 10.1016/j.cllc.2022.10.008. Epub 2022 Nov 11. PubMed 36528522 ↗

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Feb 2028, 79 months after the start.

Of 286 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 79 months is above that.

Counting every sponsor, half of 496 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2026 → Feb 2028 and completion Aug 2028 → Aug 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2021
First posted
May 14, 2021
StartActual
Jul 2, 2021
Primary completionEst.
Feb 29, 2028was Dec 2026
CompletionEst.
Aug 29, 2029was Aug 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 28, 2026
Sites
2 sites added, 2 sites removed. 84 sites changed recruiting status (34 now recruiting, 30 now active, not recruiting, …)
Show 84 sites
  • University of Alabama at Birmingham · Birmingham, United Statesno status→Recruiting
  • Precision NextGen Oncology · Beverly Hills, United Statesno status→Completed
  • City of Hope-Duarte-56419 · Duarte, United Statesno status→Recruiting
  • City of Hope - Seacliff · Huntington Beach, United Statesno status→Completed
  • City of Hope-Irvine-69674 · Irvine, United Statesno status→Completed
  • Valkyrie Clinical Trials · Los Angeles, United Statesno status→Recruiting
  • University of California Irvine · Orange, United Statesno status→Recruiting
  • University of California Davis · Sacramento, United Statesno status→Recruiting
  • Georgetown University · Washington D.C., United Statesno status→Recruiting
  • Holy Cross Hospital-Fort Lauderdale-57892 · Fort Lauderdale, United Statesno status→Recruiting
  • Winship Cancer Institute · Atlanta, United Statesno status→Recruiting
  • Hawaii Cancer Care - Honolulu · Honolulu, United Statesno status→Recruiting
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health · New York, United Statesno status→Recruiting
  • Duke University Medical Center · Durham, United Statesno status→Recruiting
  • Cleveland Clinic · Cleveland, United Statesno status→Recruiting
  • Sarah Cannon Research Institute-Nashville-48456 · Nashville, United Statesno status→Recruiting
  • Mary Crowley Cancer Research Center · Dallas, United Statesno status→Recruiting
  • The University of Texas MD Anderson Cancer Center · Houston, United Statesno status→Recruiting
  • Virginia Cancer Specialists, PC · Fairfax, United Statesno status→Recruiting
  • Fred Hutchinson Cancer Research Center · Seattle, United Statesno status→Recruiting
  • Macquarie University · Macquarie Park, Australiano status→Completed
  • Ordensklinikum Linz GmbH · Linz, Austriano status→Completed
  • Brussels - HOSP Jules Bordet · Anderlecht/Brussels-Capital, Belgiumno status→Active, not recruiting
  • Beijing Cancer Hospital · Beijing, Chinano status→Completed
  • Jilin Province Cancer Hospital · Changchun, Chinano status→Completed
  • The First Hospital of Jilin University · Changchun, Chinano status→Active, not recruiting
  • Fujian Cancer Hospital · Fuzhou, Chinano status→Active, not recruiting
  • Guangdong Provincial People's Hospital · Guangzhou, Chinano status→Active, not recruiting
  • The First Affiliated Hospital, Zhejiang University · Hangzhou, Chinano status→Active, not recruiting
  • Zhejiang Cancer Hospital · Hangzhou, Chinano status→Active, not recruiting
  • …and 54 more on the registry record
Show 2 added (1 France, 1 Israel)
  • Hopital Louis Pradel · Bron, France
  • The Chaim Sheba Medical Center Tel HaShomer · Tel HaShomer, Israel
Show 2 removed
  • Hôpital Louis Pradel · Bron, France
  • The Chaim Sheba Medical Center Tel HaShomer · Tel Litwinsky, Israel
across 3 updates, Oct 5, 2026 – Nov 12, 2026
Primary completion
Dec 30, 2026→Feb 29, 2028
Oct 28, 2026
Study completion
Aug 30, 2028→Aug 29, 2029
Oct 28, 2026
Eligibility
6 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedPatient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with non-squamous NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
  • EditedNSCLC Patient with a documented HER2 mutation outside of the tyrosine kinase domain (TKD) as per local lab results or squamous NSCLC patient with mutation in the TKD as per local lab results. After implementation of CTP v8, only non-squamous NSCLC patients with a documented activating HER2 mutation outside of the tyrosine kinase domain (TKD) as per local lab results.
  • EditedPatient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy. After implementation of CTP v8, patients who had received, in the advanced/metastatic setting, at least one line of systemic therapy OR patients who are treatment naïve for non-squamous NSCLC (no prior systemic therapy, immunotherapy or targeted therapy for stage IIIB or IV adenocarcinoma).
  • EditedNSCLC patients who are either treatment naïve or who had received any prior line of treatment, in the advanced/metastatic setting. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
  • EditedPatient should have received, in the advanced/metastatic setting, at least one line of systemic therapy that includes a platinum-based combination chemotherapy and should have been treated with previous HER2 directed antibody-drug conjugates (ADC) in the same advanced/metastatic setting and developed disease progression recurrence during or after completing this therapy. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
  • EditedPatient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
Oct 5, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5 : Objective response (OR) as assessed by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohorts 3 (patients prior to CTP v8.0), 6, 7, 8, and 9: Objective response according to RECIST 1.1 by investigator assessmentTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
Oct 5, 2026
Secondary outcomes
16 edited
What changed in the outcomes
  • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Duration of objective response (DoR) according to RECIST 1.1Time frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control (DC)Time frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Progression-free survival (PFS)Time frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response according to response assessment in neuro-oncology for brain metastases (RANO-BM) criteria as assessed by central independent review for patients with central nervous system (CNS) lesions at baselineTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control according to RANO-BM criteria as assessed by central independent review for patients with CNS lesions at baselineTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response in CNS lesions according to RECIST 1.1 criteria as assessed by central independent review for patients with CNS lesions at baselineTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control in CNS lesions according to RECIST 1.1 criteria as assessed by central independent review for patients with CNS lesions at baselineTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Duration of objective response according to RECIST 1.1 by investigator assessmentTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Disease control according to RECIST 1.1 as assessed by the investigatorTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Progression-free survival according to RECIST 1.1 as assessed by the investigatorTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Objective response according to RANO-BM criteria as assessed by the investigator for patients with CNS lesions at baselineTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Disease control according to RANO-BM criteria as assessed by the investigator for patients with CNS lesions at baselineTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohort 4: DoR in CNS lesions according to RECIST 1.1 by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohort 4: DC(1) in CNS lesions according to RECIST 1.1 by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohort 4: PFS in CNS lesions according to RECIST 1.1 as assessed by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  • EditedPhase Ib - Cohort 4: DC(2) according to RECIST 1.1 by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
Oct 5, 2026
Contact
Study contact now listed: added c•••@boehringer-ingelheim.com · •••0127; added •••0127. See the current contact
Oct 28, 2026
Site contacts
Changed at 34 sites. See the sites
Show 34 sites
  • University of Alabama at Birmingham · Birmingham, United StatesContact added u•••@bitrialsupport.com · •••2368
  • City of Hope-Duarte-56419 · Duarte, United StatesContact added u•••@bitrialsupport.com · •••2368
  • Valkyrie Clinical Trials · Los Angeles, United StatesContact added u•••@bitrialsupport.com · •••2368
  • University of California Irvine · Orange, United StatesContact added u•••@bitrialsupport.com · •••2368
  • University of California Davis · Sacramento, United StatesContact added u•••@bitrialsupport.com · •••2368
  • Georgetown University · Washington D.C., United StatesContact added u•••@bitrialsupport.com · •••2368
  • Holy Cross Hospital-Fort Lauderdale-57892 · Fort Lauderdale, United StatesContact added u•••@bitrialsupport.com · •••2368
  • Winship Cancer Institute · Atlanta, United StatesContact added u•••@bitrialsupport.com · •••2368
  • Hawaii Cancer Care - Honolulu · Honolulu, United StatesContact added u•••@bitrialsupport.com · •••2368
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health · New York, United StatesContact added u•••@bitrialsupport.com · •••2368
  • Duke University Medical Center · Durham, United StatesContact added u•••@bitrialsupport.com · •••2368
  • Cleveland Clinic · Cleveland, United StatesContact added u•••@bitrialsupport.com · •••2368
  • Sarah Cannon Research Institute-Nashville-48456 · Nashville, United StatesContact added u•••@bitrialsupport.com · •••2368
  • Mary Crowley Cancer Research Center · Dallas, United StatesContact added u•••@bitrialsupport.com · •••2368
  • The University of Texas MD Anderson Cancer Center · Houston, United StatesContact added u•••@bitrialsupport.com · •••2368
  • Virginia Cancer Specialists, PC · Fairfax, United StatesContact added u•••@bitrialsupport.com · •••2368
  • Fred Hutchinson Cancer Research Center · Seattle, United StatesContact added u•••@bitrialsupport.com · •••2368
  • Universitätsklinikum Köln (AöR) · Cologne, GermanyContact added d•••@bitrialsupport.com · •••4742
  • Technische Universität Dresden · Dresden, GermanyContact added d•••@bitrialsupport.com · •••4742
  • Justus-Liebig Universität Gießen · Giessen, GermanyContact added d•••@bitrialsupport.com · •••4742
  • Pius-Hospital, Oldenburg · Oldenburg, GermanyContact added d•••@bitrialsupport.com · •••4742
  • National Cancer Center Hospital East · Chiba, Kashiwa, JapanContact added n•••@bitrialsupport.com · •••8862
  • Shikoku Cancer Center · Ehime, Matsuyama, JapanContact added n•••@bitrialsupport.com · •••8862
  • Hiroshima University Hospital · Hiroshima, Hiroshima, JapanContact added n•••@bitrialsupport.com · •••8862
  • Osaka International Cancer Institute · Osaka, Osaka, JapanContact added n•••@bitrialsupport.com · •••8862
  • Kindai University Hospital · Osaka, Sakai, JapanContact added n•••@bitrialsupport.com · •••8862
  • Hamamatsu University Hospital · Shizuoka, Hamamatsu, JapanContact added n•••@bitrialsupport.com · •••8862
  • National Cancer Center Hospital · Tokyo, Chuo-ku, JapanContact added n•••@bitrialsupport.com · •••8862
  • Nederlands Kanker Instituut · Amsterdam, NetherlandsContact added n•••@bitrialsupport.com · •••4613
  • National Cancer Centre Singapore · Singapore, SingaporeContact added s•••@bitrialsupport.com · •••7344
  • …and 4 more sites
Oct 28, 2026
Show all 3 updates
  1. Nov 12, 2026
    Meir Medical Center is now Completed
    + 1 other change: verification date
  2. Oct 28, 2026
    Active, not recruiting→Recruiting
    1 site added, 1 site removed. 84 sites changed recruiting status (34 now recruiting, 31 now active, not recruiting, …)
    Show 84 sites
    • University of Alabama at Birmingham · Birmingham, United Statesno status→Recruiting
    • Precision NextGen Oncology · Beverly Hills, United Statesno status→Completed
    • City of Hope-Duarte-56419 · Duarte, United Statesno status→Recruiting
    • City of Hope - Seacliff · Huntington Beach, United Statesno status→Completed
    • City of Hope-Irvine-69674 · Irvine, United Statesno status→Completed
    • Valkyrie Clinical Trials · Los Angeles, United Statesno status→Recruiting
    • University of California Irvine · Orange, United Statesno status→Recruiting
    • University of California Davis · Sacramento, United Statesno status→Recruiting
    • Georgetown University · Washington D.C., United Statesno status→Recruiting
    • Holy Cross Hospital-Fort Lauderdale-57892 · Fort Lauderdale, United Statesno status→Recruiting
    • Winship Cancer Institute · Atlanta, United Statesno status→Recruiting
    • Hawaii Cancer Care - Honolulu · Honolulu, United Statesno status→Recruiting
    • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health · New York, United Statesno status→Recruiting
    • Duke University Medical Center · Durham, United Statesno status→Recruiting
    • Cleveland Clinic · Cleveland, United Statesno status→Recruiting
    • Sarah Cannon Research Institute-Nashville-48456 · Nashville, United Statesno status→Recruiting
    • Mary Crowley Cancer Research Center · Dallas, United Statesno status→Recruiting
    • The University of Texas MD Anderson Cancer Center · Houston, United Statesno status→Recruiting
    • Virginia Cancer Specialists, PC · Fairfax, United Statesno status→Recruiting
    • Fred Hutchinson Cancer Research Center · Seattle, United Statesno status→Recruiting
    • Macquarie University · Macquarie Park, Australiano status→Completed
    • Ordensklinikum Linz GmbH · Linz, Austriano status→Completed
    • Brussels - HOSP Jules Bordet · Anderlecht/Brussels-Capital, Belgiumno status→Active, not recruiting
    • Beijing Cancer Hospital · Beijing, Chinano status→Completed
    • Jilin Province Cancer Hospital · Changchun, Chinano status→Completed
    • The First Hospital of Jilin University · Changchun, Chinano status→Active, not recruiting
    • Fujian Cancer Hospital · Fuzhou, Chinano status→Active, not recruiting
    • Guangdong Provincial People's Hospital · Guangzhou, Chinano status→Active, not recruiting
    • The First Affiliated Hospital, Zhejiang University · Hangzhou, Chinano status→Active, not recruiting
    • Zhejiang Cancer Hospital · Hangzhou, Chinano status→Active, not recruiting
    • …and 54 more on the registry record
    Show site
    • The Chaim Sheba Medical Center Tel HaShomer · Tel HaShomer, Israel
    Show 1 removed
    • The Chaim Sheba Medical Center Tel HaShomer · Tel Litwinsky, Israel
    Primary completion Dec 30, 2026→Feb 29, 2028
    Study completion Aug 30, 2028→Aug 29, 2029
    Contact Study contact now listed: added c•••@boehringer-ingelheim.com · •••0127; added •••0127. See the current contact
    Site contacts Changed at 34 sites. See the sites
    Show 34 sites
    • University of Alabama at Birmingham · Birmingham, United StatesContact added u•••@bitrialsupport.com · •••2368
    • City of Hope-Duarte-56419 · Duarte, United StatesContact added u•••@bitrialsupport.com · •••2368
    • Valkyrie Clinical Trials · Los Angeles, United StatesContact added u•••@bitrialsupport.com · •••2368
    • University of California Irvine · Orange, United StatesContact added u•••@bitrialsupport.com · •••2368
    • University of California Davis · Sacramento, United StatesContact added u•••@bitrialsupport.com · •••2368
    • Georgetown University · Washington D.C., United StatesContact added u•••@bitrialsupport.com · •••2368
    • Holy Cross Hospital-Fort Lauderdale-57892 · Fort Lauderdale, United StatesContact added u•••@bitrialsupport.com · •••2368
    • Winship Cancer Institute · Atlanta, United StatesContact added u•••@bitrialsupport.com · •••2368
    • Hawaii Cancer Care - Honolulu · Honolulu, United StatesContact added u•••@bitrialsupport.com · •••2368
    • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health · New York, United StatesContact added u•••@bitrialsupport.com · •••2368
    • Duke University Medical Center · Durham, United StatesContact added u•••@bitrialsupport.com · •••2368
    • Cleveland Clinic · Cleveland, United StatesContact added u•••@bitrialsupport.com · •••2368
    • Sarah Cannon Research Institute-Nashville-48456 · Nashville, United StatesContact added u•••@bitrialsupport.com · •••2368
    • Mary Crowley Cancer Research Center · Dallas, United StatesContact added u•••@bitrialsupport.com · •••2368
    • The University of Texas MD Anderson Cancer Center · Houston, United StatesContact added u•••@bitrialsupport.com · •••2368
    • Virginia Cancer Specialists, PC · Fairfax, United StatesContact added u•••@bitrialsupport.com · •••2368
    • Fred Hutchinson Cancer Research Center · Seattle, United StatesContact added u•••@bitrialsupport.com · •••2368
    • Universitätsklinikum Köln (AöR) · Cologne, GermanyContact added d•••@bitrialsupport.com · •••4742
    • Technische Universität Dresden · Dresden, GermanyContact added d•••@bitrialsupport.com · •••4742
    • Justus-Liebig Universität Gießen · Giessen, GermanyContact added d•••@bitrialsupport.com · •••4742
    • Pius-Hospital, Oldenburg · Oldenburg, GermanyContact added d•••@bitrialsupport.com · •••4742
    • National Cancer Center Hospital East · Chiba, Kashiwa, JapanContact added n•••@bitrialsupport.com · •••8862
    • Shikoku Cancer Center · Ehime, Matsuyama, JapanContact added n•••@bitrialsupport.com · •••8862
    • Hiroshima University Hospital · Hiroshima, Hiroshima, JapanContact added n•••@bitrialsupport.com · •••8862
    • Osaka International Cancer Institute · Osaka, Osaka, JapanContact added n•••@bitrialsupport.com · •••8862
    • Kindai University Hospital · Osaka, Sakai, JapanContact added n•••@bitrialsupport.com · •••8862
    • Hamamatsu University Hospital · Shizuoka, Hamamatsu, JapanContact added n•••@bitrialsupport.com · •••8862
    • National Cancer Center Hospital · Tokyo, Chuo-ku, JapanContact added n•••@bitrialsupport.com · •••8862
    • Nederlands Kanker Instituut · Amsterdam, NetherlandsContact added n•••@bitrialsupport.com · •••4613
    • National Cancer Centre Singapore · Singapore, SingaporeContact added s•••@bitrialsupport.com · •••7344
    • …and 4 more sites
    + 1 other change: verification date
  3. Oct 5, 2026
    1 site added, 1 site removed
    Show site
    • Hopital Louis Pradel · Bron, France
    Show 1 removed
    • Hôpital Louis Pradel · Bron, France
    Eligibility 6 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with non-squamous NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
    • EditedNSCLC Patient with a documented HER2 mutation outside of the tyrosine kinase domain (TKD) as per local lab results or squamous NSCLC patient with mutation in the TKD as per local lab results. After implementation of CTP v8, only non-squamous NSCLC patients with a documented activating HER2 mutation outside of the tyrosine kinase domain (TKD) as per local lab results.
    • EditedPatient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy. After implementation of CTP v8, patients who had received, in the advanced/metastatic setting, at least one line of systemic therapy OR patients who are treatment naïve for non-squamous NSCLC (no prior systemic therapy, immunotherapy or targeted therapy for stage IIIB or IV adenocarcinoma).
    • EditedNSCLC patients who are either treatment naïve or who had received any prior line of treatment, in the advanced/metastatic setting. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
    • EditedPatient should have received, in the advanced/metastatic setting, at least one line of systemic therapy that includes a platinum-based combination chemotherapy and should have been treated with previous HER2 directed antibody-drug conjugates (ADC) in the same advanced/metastatic setting and developed disease progression recurrence during or after completing this therapy. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
    • EditedPatient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5 : Objective response (OR) as assessed by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohorts 3 (patients prior to CTP v8.0), 6, 7, 8, and 9: Objective response according to RECIST 1.1 by investigator assessmentTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    Secondary outcomes 16 edited
    What changed in the outcomes
    • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Duration of objective response (DoR) according to RECIST 1.1Time frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control (DC)Time frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Progression-free survival (PFS)Time frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response according to response assessment in neuro-oncology for brain metastases (RANO-BM) criteria as assessed by central independent review for patients with central nervous system (CNS) lesions at baselineTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control according to RANO-BM criteria as assessed by central independent review for patients with CNS lesions at baselineTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response in CNS lesions according to RECIST 1.1 criteria as assessed by central independent review for patients with CNS lesions at baselineTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control in CNS lesions according to RECIST 1.1 criteria as assessed by central independent review for patients with CNS lesions at baselineTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Duration of objective response according to RECIST 1.1 by investigator assessmentTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Disease control according to RECIST 1.1 as assessed by the investigatorTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Progression-free survival according to RECIST 1.1 as assessed by the investigatorTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Objective response according to RANO-BM criteria as assessed by the investigator for patients with CNS lesions at baselineTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Disease control according to RANO-BM criteria as assessed by the investigator for patients with CNS lesions at baselineTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohort 4: DoR in CNS lesions according to RECIST 1.1 by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohort 4: DC(1) in CNS lesions according to RECIST 1.1 by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohort 4: PFS in CNS lesions according to RECIST 1.1 as assessed by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    • EditedPhase Ib - Cohort 4: DC(2) according to RECIST 1.1 by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04886804
Responsible party
Sponsor
First posted
May 14, 2021
Start date
Jul 2, 2021
Primary completion
Feb 29, 2028 (estimated)
Completion
Aug 29, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127
Additional US locations available on demand. Please contact for options.
Contact
1-800-243-0127

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zongertinib

Start the discussion